Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Lisocabtagene Maraleucel (liso-cel) for Treatment of Second-Line Transplant Noneligible (TNE) Relapsed/Refractory (R/R) Aggressive Non-Hodgkin Lymphoma (NHL): Initial Results from the PILOT Study

Alison R. Sehgal, MD, John Godwin, John Pribble, Lei Wang, PhD, Jerill Thorpe, BSc, Gerhard C. Hildebrandt, MD

Blood (2019) 134 (Supplement_1): 2882.

https://doi.org/10.1182/blood-2019-127658

Published: 2019

Journal Articles

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

Carlos R. Bachier, MD, Maria Lia Palomba, MD, Jeremy S. Abramson, MD MMSc, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, John Godwin, Gerhard C. Hildebrandt, MD, Tanya Siddiqi, MD, Don Stevens, MD, Thalia Farazi, Ana Kostic, Nikolaus S. Trede, Lei Wang, PhD, James Lymp, PhD, Tennille Thelen, Ken Ogasawara, David G. Maloney, MD PhD

Blood (2019) 134 (Supplement_1): 2868.

https://doi.org/10.1182/blood-2019-127566

Published: 2019

Journal Articles

Bone Marrow T Cell Changes By Multiplex IHC after Treatment with Flotetuzumab, a CD123 x CD3 Bispecific Dart ® Protein, in a Primary Refractory t-AML Patient

John Godwin, MD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Helene Lelièvre, PhD PharmD, Jon Wigginton, MD, Jan K Davidson-Moncada, MD PhD, Bernard Fox, PhD

Blood (2018) 132 (Supplement 1): 4065.

https://doi.org/10.1182/blood-2018-99-118522

Published: 2018

Journal Articles

2 nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials

Megan Othus, PhD, Elihu H. Estey, MD, Guillermo Garcia-Manero, MD, Brent Wood, MD PhD, Derek Stirewalt, MD, John Godwin, MD, James K. Weick, MD, Jeanne E. Anderson, MD, Frederick R. Appelbaum, MD, Harry P. Erba, MD PhD, Roland B. Walter, MD PhD MS

Blood (2018) 132 (Supplement 1): 3978.

https://doi.org/10.1182/blood-2018-99-117525

Published: 2018

Journal Articles

Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart ® Molecule for T-Cell Redirected Therapy

Blood (2018) 132 (Supplement 1): 2738.

https://doi.org/10.1182/blood-2018-99-112615

Published: 2018

Journal Articles

FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years

James M. Foran, MD, Zhuoxin Sun, PhD, Elisabeth Paietta, PhD, Janis Racevskis, PhD, David F. Claxton, MD, Hillard M Lazarus, MD, Daniel A. Arber, MD, Jacob M. Rowe, MD, John Godwin, MD, Yanming Zhang, MD, Martin S. Tallman, MD, Mark R. Litzow, MD, Keith W. Pratz, MD, Selina Luger, MD

Blood (2018) 132 (Supplement 1): 3995.

https://doi.org/10.1182/blood-2018-99-117838

Published: 2018

Journal Articles

Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial

Blood (2018) 132 (Supplement 1): 437.

https://doi.org/10.1182/blood-2018-99-113950

Published: 2018

Journal Articles

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart ® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2018) 132 (Supplement 1): 764.

https://doi.org/10.1182/blood-2018-99-117085

Published: 2018

Journal Articles

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Blood (2017) 130 (Supplement 1): 637.

https://doi.org/10.1182/blood.V130.Suppl_1.637.637

Published: 2017

Journal Articles

Lead-in Dose Optimization to Mitigate Cytokine Release Syndrome in AML and MDS Patients Treated with Flotetuzumab, a CD123 x CD3 Dart® Molecule for T-Cell Redirected Therapy

Blood (2017) 130 (Supplement 1): 3856.

https://doi.org/10.1182/blood.V130.Suppl_1.3856.3856

Published: 2017

Journal Articles

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

Michael P Rettig, PhD, John Godwin, MD, Norbert Vey, Bernard Fox, PhD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Daner Li, MS, Daniel Primo, PhD, Joan Ballesteros, PhD, Jichao Sun, PhD, Helene Lelièvre, PhD PharmD, Jan Baughman, MPH, Ross La Motte-Mohs, PhD, John Muth, MS, Paul Moore, PhD, Ezio Bonvini, MD, Jon Wigginton, John F DiPersio, MD PhD, Jan Davidson-Moncada, MDPhD

Blood (2017) 130 (Supplement 1): 1365.

https://doi.org/10.1182/blood.V130.Suppl_1.1365.1365

Published: 2017

Journal Articles

Associations between Complete Remissions (CRs) with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia and 2-3 Year Survival ("Potential Cure") over the Past Four Decades: Analysis of SWOG Trial Data

Megan Othus, PhD, Guillermo Garcia-Manero, MD, John Godwin, MD, James K. Weick, MD, Jeanne E. Anderson, MD, Derek Stirewalt, MD, Frederick R. Appelbaum, MD, Harry P. Erba, MD PhD, Elihu H. Estey, MD

Blood (2017) 130 (Supplement 1): 1301.

https://doi.org/10.1182/blood.V130.Suppl_1.1301.1301

Published: 2017

Journal Articles

Prediction Of CR On Reinduction In Patients With Newly Diagnosed Acute Myeloid Leukemia Given Intensive Induction Regimens: A Report From SWOG and Cleveland Clinic

Megan Othus, PhD, Mukherjee Sudipto, MD, Mikkael A. Sekeres, MD, MS, John Godwin, MD, Jeanne E. Anderson, MD, Stephen Petersdorf, MD, Frederick R. Appelbaum, MD, Harry P Erba, MD, Elihu H. Estey, MD

Blood (2013) 122 (21): 3924.

https://doi.org/10.1182/blood.V122.21.3924.3924

Published: 2013

Journal Articles

Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/Or FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report

Farhad Ravandi, MD, Megan Othus, PhD, Stefan H. Faderl, MD, Derek L. Stirewalt, MD, Sherry R. Pierce, RN, BS, Gautam Borthakur, MD, John Godwin, MD, Jeanne E. Anderson, MD, Stephen Petersdorf, MD, Jorge E. Cortes, MD, Fabiana Ostronoff, MD, Era Pogosova-Agadijanyan, MD, Frederick R. Appelbaum, MD, Hagop M. Kantarjian, MD, Elihu H. Estey, MD

Blood (2013) 122 (21): 2686.

https://doi.org/10.1182/blood.V122.21.2686.2686

Published: 2013

Journal Articles

Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome

Azra Raza, Naomi Galili, Scott Smith, John Godwin, Jeffrey Lancet, Magda Melchert, Marsha Jones, James G. Keck, Lisa Meng, Gail L. Brown, Alan List

Blood (2009) 113 (26): 6533–6540.

https://doi.org/10.1182/blood-2009-01-176032

Published: 2009

Journal Articles

Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials

Nataliya Kuptsova, Kenneth J. Kopecky, John Godwin, Jeanne Anderson, Ashraful Hoque, Cheryl L. Willman, Marilyn L. Slovak, Christine B. Ambrosone

Blood (2007) 109 (9): 3936–3944.

https://doi.org/10.1182/blood-2006-05-022111

Published: 2007

Journal Articles

Azacitidine Plus Gemtuzumab Ozogamicin (GO): A Novel Combination in the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS) in the Elderly.

Sucha Nand, MD, John Godwin, MD, Scott Smith, MD, Kevin Barton, MD, Eliza Germano, BSN, Patrick Stiff, MD

Blood (2006) 108 (11): 1981.

https://doi.org/10.1182/blood.V108.11.1981.1981

Published: 2006

Journal Articles

Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction

Blood (2006) 108 (2): 685–696.

https://doi.org/10.1182/blood-2004-12-4633

Published: 2006

Includes: Supplemental data

Journal Articles

Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines

Christiane Houde, Yulin Li, Lynda Song, Kevin Barton, Qing Zhang, John Godwin, Sucha Nand, Amir Toor, Serhan Alkan, N. Veronique Smadja, Hervé Avet-Loiseau, Carmen S. Lima, Lucio Miele, Lionel J. Coignet

Blood (2004) 104 (12): 3697–3704.

https://doi.org/10.1182/blood-2003-12-4114

Published: 2004

Journal Articles

Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study

Catherine P. Leith, Kenneth J. Kopecky, John Godwin, Thomas McConnell, Marilyn L. Slovak, I-Ming Chen, David R. Head, Frederick R. Appelbaum, Cheryl L. Willman

Blood (1997) 89 (9): 3323–3329.

https://doi.org/10.1182/blood.V89.9.3323

Published: 1997

NARROW

Lisocabtagene Maraleucel (liso-cel) for Treatment of Second-Line Transplant Noneligible (TNE) Relapsed/Refractory (R/R) Aggressive Non-Hodgkin Lymphoma (NHL): Initial Results from the PILOT Study

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

Bone Marrow T Cell Changes By Multiplex IHC after Treatment with Flotetuzumab, a CD123 x CD3 Bispecific Dart ® Protein, in a Primary Refractory t-AML Patient

2 nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials

Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart ® Molecule for T-Cell Redirected Therapy

FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years

Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart ® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Lead-in Dose Optimization to Mitigate Cytokine Release Syndrome in AML and MDS Patients Treated with Flotetuzumab, a CD123 x CD3 Dart® Molecule for T-Cell Redirected Therapy

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

Associations between Complete Remissions (CRs) with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia and 2-3 Year Survival ("Potential Cure") over the Past Four Decades: Analysis of SWOG Trial Data

Prediction Of CR On Reinduction In Patients With Newly Diagnosed Acute Myeloid Leukemia Given Intensive Induction Regimens: A Report From SWOG and Cleveland Clinic

Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/Or FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report

Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome

Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials

Azacitidine Plus Gemtuzumab Ozogamicin (GO): A Novel Combination in the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS) in the Elderly.

Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction

Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines

Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only